THERACLION: directors' dealings · France · AMF

About THERACLION

THERACLION is a French medtech company focused on non-invasive medical treatment using focused ultrasound and robotics. Listed on Euronext Growth Paris under ISIN FR0010120402, the company develops extracorporeal surgery platforms designed to replace, in selected indications, more invasive procedures performed in an operating room. Its market positioning is built around a clear value proposition: reduce invasiveness, lower healthcare-system costs, and improve the patient journey through treatments that require no incision, leave no scar, and allow rapid recovery. Theraclion’s history dates back to 2004, when the research phase began. The company then reached several industrial and clinical milestones, including delivery of ECHOPULSE in 2014, the launch of SONOVEIN in 2019, and the introduction of SONOVEIN HD in 2022. The company is headquartered in Malakoff, near Paris, where its management, research, operations, and regulatory teams are based. This evolution shows a gradual transition from laboratory innovation to a commercial medical-device offering aimed at hospitals, specialty centers, and certain office-based practices. Theraclion’s product portfolio is organized around two main platforms. SONOVEIN is its robotic echotherapy system for the treatment of varicose veins, which the company describes as a 100% non-invasive solution. ECHOPULSE targets thyroid nodules and breast fibroadenomas. Today, Theraclion’s industrial and commercial strategy is primarily centered on SONOVEIN, which is the main driver of growth and international expansion. According to the company, the platform is now present in more than 10 countries, and more than 15 countries in some recent communications, underscoring the ongoing geographic rollout beyond France. From a competitive standpoint, Theraclion operates in a highly specialized niche at the intersection of healthcare, medical imaging, robotics, and therapeutic ultrasound. Its differentiation lies in SONOVEIN’s non-invasive profile, real-time imaging integration, and workflow designed to be handled by a single operator without the need for an operating room or anesthesia. In 2026, the company also announced a €6 million capital increase, highlighting the financing needs typically associated with development-stage medtech companies and commercial scale-up. For investors, Theraclion remains a speculative growth stock, exposed to regulatory, clinical, and commercialization risks, but supported by a distinctive technology platform in non-invasive treatment of venous disease.